After my IPF diagnosis, I adopted a mantra: ‘Be positive in all things’

1st patient dosed in Phase 2a trial of BBT-877 for IPF

The first participant has been dosed in a clinical trial testing the experimental anti-fibrotic therapy BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The milestone was announced by BBT-877’s developer Bridge Biotherapeutics, which initiated the trial late last year. “The first patient dosing of BBT-877 marks an…

What happened after COVID-19 finally caught up to me

American comedian Bill Engvall is known for his punchline “Here’s your sign,” which he’d often say in response to an outrageously obvious question. I recently experienced two “here’s your sign” moments of my own after wondering if I’d contracted the virus that causes COVID-19. On Monday, April 3, I…

MMP19 protein may be therapeutic target for IPF

The protein matrix metalloproteinase 19 (MMP19) plays an important role in regulating cellular processes in the lining of blood vessels that contribute to lung fibrosis occurring in idiopathic pulmonary fibrosis (IPF), a new study reveals. “Vascular integrity regulated by MMP19 could be a promising therapeutic target for suppressing pulmonary…